Equity · Healthcare
BVS
NASDAQBioventus (BVS)
The line runs 13.91 USD on 12 August through 11.02 USD on 9 November, on a scale from 10 to 16. Days the market did not trade hold the previous close, flat.
- Market cap
- 783.4M USD
- P/E (TTM)
- 13.8
- Revenue, year to Dec 2025
- 568.1M USD
- EPS, diluted, year to Dec 2025
- 0.33 USD
- 52-week range
- 6.51 USD – 15.30 USD
- Avg volume
- 38.6K
- Mentions, 30 days
- 1
as of Nov 9, 2026
Have Bioventus (BVS) insiders bought or sold shares recently?
BVS's newest Form 4 filing is dated 2 June 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Mar 2026 | McMurry-Heath MichelleDirector | Sell | 12,000 | 105K USD |
| 04 Dec 2025 | NOHRA GUY P | Sell | 10,000 | 76K USD |
| 07 Nov 2025 | McMurry-Heath Michelle | Sell | 17,701 | 131K USD |
| Sold | 3 open-market sales | 39,701 | $312K |
34 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Jun 2026 | Bartholdson John A.Director | Option exercise | 32,282 | |
| 02 Jun 2026 | Beyer PatDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | SUTTER MARTIN PDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | HAWKINS WILLIAM ADirector | Option exercise | 39,789 | |
| 02 Jun 2026 | NOHRA GUY PDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | STALNECKER SUSAN MDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | NEELS GUIDO JDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | Cowdy Philip G.Director | Option exercise | 32,282 | |
| 02 Jun 2026 | Ladone Mary KayDirector | Option exercise | 32,282 | |
| 02 Jun 2026 | McMurry-Heath MichelleDirector | Option exercise | 32,282 | |
| 10 Apr 2026 | CHURCH KATRINA JSVP & Chief Compliance Officer | Option exercise | 4,300 | |
| 10 Apr 2026 | CHURCH KATRINA JSVP & Chief Compliance Officer | Tax withheld | 1,868 | 17K USD |
Showing the 12 most recent of 34 compensation filings in this window. The figures above count all of them.
Which funds hold Bioventus (BVS)?
8 of the 45 institutional funds we track reported a Bioventus position for the quarter ended 30 Jun 2026 — a combined 17.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Added | 736,000 | 6.9M USD | +50.4% |
| AQR Capital Management | Held (±25%) | 326,124 | 3.1M USD | −4.1% |
| Two Sigma Investments | Held (±25%) | 230,625 | 2.2M USD | −11.0% |
| Millennium Management | Added | 203,512 | 1.9M USD | +1,123.5% |
| Point72 Asset Management | New position | 169,713 | 1.6M USD | |
| Man Group | New position | 64,589 | 610K USD | |
| Tudor Investment Corp | New position | 61,117 | 577K USD | |
| D. E. Shaw & Co. | Trimmed | 47,304 | 447K USD | −84.8% |
| Balyasny Asset Management | Exited | |||
| Citadel Advisors | Exited |
What has been filed or recorded for Bioventus (BVS)?
The filings we hold for Bioventus, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 32,758 shares | 416K USD notional · 0.047% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 92 shares | 1K USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 96 shares | 1K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 11,432 shares | 154K USD notional · 0.016% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,756 shares | 51K USD notional · 0.005% of shares out |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 251 shares | 4K USD notional · <0.001% of shares out |
| 26 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.08 USD | Revenue $142M |
| 26 Sep 2026 | Financials | Total assets | 673.4M USD | at period end |
| 26 Sep 2026 | Financials | Total equity | 240.5M USD | at period end |
| 27 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.47 USD | Revenue $153M |
| 28 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.04 USD | Revenue $132M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.33 USD | Revenue $568M |
| 31 Dec 2025 | Financials | Revenue | 568.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 22.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.33 USD | fiscal year |
| 27 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.05 USD | Revenue $139M |
| 28 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.11 USD | Revenue $148M |
| 29 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.04 USD | Revenue $124M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.56 USD | Revenue $573M |
What is Reddit saying about Bioventus (BVS)?
Reddit mentioned BVS 1 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Bioventus (BVS) compare with its price?
Share ↗
Which subreddits are talking about Bioventus (BVS)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/ausfinance | 100% | 1 | +0.09 |
What do people ask about Bioventus (BVS)?
What did Bioventus shares close at?11.02
Bioventus closed at 11.02 USD on 9 Nov 2026, up 3.92% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Bioventus’ market cap?783.4M
Bioventus is worth 783.4M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Bioventus’ P/E ratio?13.8
Bioventus has a price-to-earnings ratio of 13.8, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Bioventus’ revenue?568.1M
Bioventus reported revenue of 568.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Bioventus insiders bought or sold shares recently?
No Bioventus insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 2 Jun 2026 (SEC Form 4). See Insiders
Which funds own Bioventus?8 of 45
8 of the 45 funds we track reported a Bioventus position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, AQR Capital Management and Two Sigma Investments. See Funds
When did Bioventus last report earnings?0.08
Bioventus last reported earnings on 26 Sep 2026 for Q3 2026, with EPS of 0.08 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Bioventus?0 mentions
Bioventus was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 26 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings